The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro
Preprint
Abstract
While vaccines are vital for preventing COVID-19 infections, it is critical to develop new therapies to treat patients who become infected. Pharmacological targeting of a host factor required for viral replication can suppress viral spread with a low probability of viral mutation leading to resistance. In particular, host kinases are highly druggable targets and a number of conserved coronavirus proteins, notably the nucleoprotein (N), require phosphorylation for full functionality. In order to understand how targeting kinases could be used to compromise viral replication, we used a combination of phosphoproteomics and bioinformatics as well as genetic and pharmacological kinase inhibition to define the enzymes important for SARS-CoV-2 N protein phosphorylation and viral replication. From these data, we propose a model whereby SRPK1/2 initiates phosphorylation of the N protein, which primes for further phosphorylation by GSK-3α/β and CK1 to achieve extensive phosphorylation of the N protein SR-rich domain. Importantly, we were able to leverage our data to identify an FDA-approved kinase inhibitor, Alectinib, that suppresses N phosphorylation by SRPK1/2 and limits SARS-CoV-2 replication. Together, these data suggest that repurposing or developing novel host-kinase directed therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.Keywords
This publication has 73 references indexed in Scilit:
- PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouseNucleic Acids Research, 2011
- MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomicsNature Methods, 2011
- A Tissue-Specific Atlas of Mouse Protein Phosphorylation and ExpressionCell, 2010
- Inhibition of Hepatitis C Virus Replication by a Specific Inhibitor of Serine-Arginine-Rich Protein KinaseAntimicrobial Agents and Chemotherapy, 2010
- Regulation of the subcellular distribution of key cellular RNA-processing factors during permissive human cytomegalovirus infectionJournal of General Virology, 2010
- Target-Decoy Search Strategy for Mass Spectrometry-Based Proteomics2009
- Coronavirus N Protein N-Terminal Domain (NTD) Specifically Binds the Transcriptional Regulatory Sequence (TRS) and Melts TRS-cTRS RNA DuplexesJournal of Molecular Biology, 2009
- Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperonesGenes & Development, 2009
- Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometryNature Methods, 2007
- Utilization of host SR protein kinases and RNA-splicing machinery during viral replicationProceedings of the National Academy of Sciences, 2006